The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.
JNK signalling in cancer: in need of new, smarter therapeutic targets
Open accessAbstract
The JNKs are master protein kinases that regulate many physiological processes, including inflammatory responses, morphogenesis, cell proliferation, differentiation, survival and death. It is increasingly apparent that persistent activation of JNKs is involved in cancer development and progression. Therefore, JNKs represent attractive targets for therapeutic intervention with small molecule kinase inhibitors. However, evidence supportive of a tumour suppressor role for the JNK proteins has also been documented. Recent studies showed that the two major JNK proteins, JNK 1 and JNK 2, have distinct or even opposing functions in different types of cancer. As such, close consideration of which JNK proteins are beneficial targets and, more importantly, what effect small molecule inhibitors of JNKs have on physiological processes, are essential. A number of ATP‐competitive and ATP‐non‐competitive JNK inhibitors have been developed, but have several limitations such as a lack of specificity and cellular toxicity. In this review, we summarize the accumulating evidence supporting a role for the JNK proteins in the pathogenesis of different solid and haematological malignancies, and discuss many challenges and scientific opportunities in the targeting of JNKs in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases
Johnson, G. L., & Lapadat, R. (2002) · Science · doi:10.1126/science.1072682 · Cited by 4,295
Signal transduction by the JNK group of MAP kinases
Davis, R. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00116-1 · Cited by 4,237
Llovet, J. M., Burroughs, A., & Bruix, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14964-1 · Cited by 3,608
A central role for JNK in obesity and insulin resistance
Hirosumi, J., Tuncman, G., Chang, L., Görgün, C. Z., Uysal, K. T., Maeda, K., Karin, M., & Hotamisligil, G. S. (2002) · Nature · doi:10.1038/nature01137 · Cited by 3,359
Dérijard, B., Hibi, M., Wu, I.-H., Barrett, T., Su, B., Deng, T., Karin, M., & Davis, R. J. (1994) · Cell · doi:10.1016/0092-8674(94)90380-8 · Cited by 3,188
Signal integration by JNK and p38 MAPK pathways in cancer development
Wagner, E. F., & Nebreda, Á. R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2694 · Cited by 2,586
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase
Bennett, B. L., Sasaki, D. T., Murray, B. W., O'Leary, E. C., Sakata, S. T., Xu, W., Leisten, J. C., Motiwala, A., Pierce, S., Satoh, Y., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251194298 · Cited by 2,558 · cited 8×
“MAPKs are activated via a BJP British Journal ofPharmacology DOI:10.1111/bph.12432 www.brjpharmacol.org 24 British Journal of Pharmacology (2014) 171 24–37 © 2013 The British Pharmacological Society kinase signalling cascade in which a MAP3K activates a MAP2K, that in turn activates a MAPK.”
BackgroundInfluentialAP-1: a double-edged sword in tumorigenesis
Eferl, R., & Wagner, E. F. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1209 · Cited by 2,242
Hepatocellular carcinoma pathogenesis: from genes to environment
Farazi, P. A., & DePinho, R. A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1934 · Cited by 1,979
The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., & Brinster, R. L. (1985) · Nature · doi:10.1038/318533a0 · Cited by 1,779
Requirement of JNK for Stress- Induced Activation of the Cytochrome c-Mediated Death Pathway
Tournier, C., Hess, P., Yang, D. D., Xu, J., Turner, T. K., Nimnual, A., Bar-Sagi, D., Jones, S. N., Flavell, R. A., & Davis, R. J. (2000) · Science · doi:10.1126/science.288.5467.870 · Cited by 1,728
The molecular biology of chronic myeloid leukemia
Deininger, M. W. N., Goldman, J. M., & Melo, J. V. (2000) · Blood · doi:10.1182/blood.v96.10.3343 · Cited by 1,667
The specificities of protein kinase inhibitors: an update
BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369 · cited 6×
“MAPKs are activated via a BJP British Journal ofPharmacology DOI:10.1111/bph.12432 www.brjpharmacol.org 24 British Journal of Pharmacology (2014) 171 24–37 © 2013 The British Pharmacological Society kinase signalling cascade in which a MAP3K activates a MAP2K, that in turn activates a MAPK.”
BackgroundInfluentialEstey, E., & Döhner, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69780-8 · Cited by 1,296
Primary brain tumours in adults
Ricard, D., Idbaih, A., Ducray, F., Lahutte, M., Hoang-Xuan, K., & Delattre, J.-Y. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61346-9 · Cited by 1,201
Maeda, S., Kamata, H., Luo, J.-L., Leffert, H., & Karin, M. (2005) · Cell · doi:10.1016/j.cell.2005.04.014 · Cited by 1,164
BH3-Only Proteins—Essential Initiators of Apoptotic Cell Death
Huang, D. C. S., & Strasser, A. (2000) · Cell · doi:10.1016/s0092-8674(00)00187-2 · Cited by 1,043
Yamamoto, K., Ichijo, H., & Korsmeyer, S. J. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.12.8469 · Cited by 1,003
Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple Myeloma
Keats, J. J., Fonseca, R., Chesi, M., Schop, R., Baker, A., Chng, W.-J., Van Wier, S., Tiedemann, R., Shi, C.-X., Sebag, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.07.003 · Cited by 983
Annunziata, C. M., Davis, R. E., Demchenko, Y., Bellamy, W., Gabrea, A., Zhan, F., Lenz, G., Hanamura, I., Wright, G., Xiao, W., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.07.004 · Cited by 952
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors
Jagtap, P., & Szabó, C. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1718 · Cited by 896
Smeal, T., Binetruy, B., Mercola, D. A., Birrer, M., & Karin, M. (1991) · Nature · doi:10.1038/354494a0 · Cited by 789
Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases
Owens, D. M., & Keyse, S. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210412 · Cited by 777
A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia
Borsello, T., Clarke, P. G. H., Hirt, L., Vercelli, A., Repici, M., Schorderet, D. F., Bogousslavsky, J., & Bonny, C. (2003) · Nature Medicine · doi:10.1038/nm911 · Cited by 658
Deletion of NEMO/IKKγ in Liver Parenchymal Cells Causes Steatohepatitis and Hepatocellular Carcinoma
Luedde, T., Beraza, N., Kotsikoris, V., van Loo, G., Nenci, A., De Vos, R., Roskams, T., Trautwein, C., & Pasparakis, M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.016 · Cited by 597
Targeting JNK for therapeutic benefit: from junk to gold?
Manning, A. M., & Davis, R. J. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1132 · Cited by 585
Uses for JNK: the Many and Varied Substrates of the c-Jun N-Terminal Kinases
Bogoyevitch, M. A., & Kobe, B. (2006) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00025-06 · Cited by 573
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
Hideshima, T., Mitsiades, C., Akiyama, M., Hayashi, T., Chauhan, D., Richardson, P., Schlossman, R., Podar, K., Munshi, N. C., Mitsiades, N., et al. (2003) · Blood · doi:10.1182/blood-2002-08-2543 · Cited by 566
MEKK1/JNK signaling stabilizes and activates p53
Fuchs, S. Y., Adler, V., Pincus, M. R., & Ronai, Z. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10541 · Cited by 524
Seki, E., Brenner, D. A., & Karin, M. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.004 · Cited by 487
Tobacco Smoke Promotes Lung Tumorigenesis by Triggering IKKβ- and JNK1-Dependent Inflammation
Takahashi, H., Ogata, H., Nishigaki, R., Broide, D. H., & Karin, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.008 · Cited by 438
Hunot, S., Vila, M., Teismann, P., Davis, R. J., Hirsch, E. C., Przedborski, S., Rakic, P., & Flavell, R. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307453101 · Cited by 426
Sakurai, T., Maeda, S., Chang, L., & Karin, M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603499103 · Cited by 400
Distinct Roles for JNK1 and JNK2 in Regulating JNK Activity and c-Jun-Dependent Cell Proliferation
Sabapathy, K., Hochedlinger, K., Nam, S. Y., Bauer, A., Karin, M., & Wagner, E. F. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.08.028 · Cited by 396
The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation.
Raitano, A. B., Halpern, J. R., Hambuch, T. M., & Sawyers, C. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.25.11746 · Cited by 394
Interaction of phosphorylated c-Jun with TCF4 regulates intestinal cancer development
Nateri, A. S., Spencer-Dene, B., & Behrens, A. (2005) · Nature · doi:10.1038/nature03914 · Cited by 375
Discovery of Potent and Selective Covalent Inhibitors of JNK
Zhang, T., Inesta-Vaquera, F., Niepel, M., Zhang, J., Ficarro, S. B., Machleidt, T., Xie, T., Marto, J. A., Kim, N., Sim, T., et al. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.11.010 · Cited by 349
Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide
Kaneto, H., Nakatani, Y., Miyatsuka, T., Kawamori, D., Matsuoka, T.-A., Matsuhisa, M., Kajimoto, Y., Ichijo, H., Yamasaki, Y., & Hori, M. (2004) · Nature Medicine · doi:10.1038/nm1111 · Cited by 337
Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis
Srivastava, R. K., Mi, Q.-S., Hardwick, J. M., & Longo, D. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3775 · Cited by 336
Targeting the Eukaryotic Translation Initiation Factor 4E for Cancer Therapy
Graff, J. R., Konicek, B. W., Carter, J. H., & Marcusson, E. G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5635 · Cited by 332
c-Jun N-terminal kinase (JNK) signaling: Recent advances and challenges
Bogoyevitch, M. A., Ngoei, K. R. W., Zhao, T. T., Yeap, Y. Y. C., & Ng, D. C. H. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.11.002 · Cited by 323
Bharti, A. C., Shishodia, S., Reuben, J. M., Weber, D., Alexanian, R., Raj-Vadhan, S., Estrov, Z., Talpaz, M., & Aggarwal, B. B. (2004) · Blood · doi:10.1182/blood-2003-06-2151 · Cited by 318
Hui, L., Zatloukal, K., Scheuch, H., Stepniak, E., & Wagner, E. F. (2008) · Journal of Clinical Investigation · doi:10.1172/jci37156 · Cited by 307
Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125
Heo, Y., Kim, S., Seo, C. I., Kim, Y. K., Sung, B., Lee, H. S., Lee, J. I., Park, S., Kim, J. H., Hwang, K. Y., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600212 · Cited by 275 · cited 8×
“MAPKs are activated via a BJP British Journal ofPharmacology DOI:10.1111/bph.12432 www.brjpharmacol.org 24 British Journal of Pharmacology (2014) 171 24–37 © 2013 The British Pharmacological Society kinase signalling cascade in which a MAP3K activates a MAP2K, that in turn activates a MAPK.”
BackgroundInfluentialCilloni, D., & Saglio, G. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1613 · Cited by 274
Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin
Min, L., Ji, Y., Bakiri, L., Qiu, Z., Cen, J., Chen, X., Chen, L., Scheuch, H., Zheng, H., Qin, L., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2590 · Cited by 246
Requirement of the JIP1 scaffold protein for stress-induced JNK activation
Whitmarsh, A. J., Kuan, C.-Y., Kennedy, N. J., Kelkar, N., Haydar, T. F., Mordes, J. P., Appel, M., Rossini, A. A., Jones, S. N., Flavell, R. A., et al. (2001) · Genes & Development · doi:10.1101/gad.922801 · Cited by 238
Papa, S., Bubici, C., Zazzeroni, F., Pham, C. G., Kuntzen, C., Knabb, J. R., Dean, K., & Franzoso, G. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401865 · Cited by 235
Self-citationSuppression of skin tumorigenesis in c-Jun NH(2)-terminal kinase-2-deficient mice.
Chen, N., Nomura, M., She, Q., Ma, W. Y., Bode, A. M., Wang, L. Q., Flavell, R. A., & Dong, Z. (2001) · PubMed · Cited by 213
Identification of the Critical Features of a Small Peptide Inhibitor of JNK Activity
Barr, R. K., Kendrick, T. S., & Bogoyevitch, M. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107565200 · Cited by 211
Chauhan, D., Li, G., Hideshima, T., Podar, K., Mitsiades, C., Mitsiades, N., Munshi, N., Kharbanda, S., & Anderson, K. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c300076200 · Cited by 208
Webster, M. A., Hutchinson, J. N., Rauh, M. J., Muthuswamy, S. K., Anton, M., Tortorice, C. G., Cardiff, R. D., Graham, F. L., Hassell, J. A., & Muller, W. J. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.4.2344 · Cited by 200
Oncogenic transformation by ras and fos is mediated by c-Jun N-terminal phosphorylation
Behrens, A., Jochum, W., Sibilia, M., & Wagner, E. F. (2000) · Oncogene · doi:10.1038/sj.onc.1203603 · Cited by 199
JNK1-dependent PUMA Expression Contributes to Hepatocyte Lipoapoptosis
Cazanave, S. C., Mott, J. L., Elmi, N. A., Bronk, S. F., Werneburg, N. W., Akazawa, Y., Kahraman, A., Garrison, S. P., Zambetti, G. P., Charlton, M. R., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.022491 · Cited by 191
Development of Spontaneous Mammary Tumors in BALB/c p53 Heterozygous Mice
Kuperwasser, C., Hurlbut, G. D., Kittrell, F. S., Dickinson, E. S., Laucirica, R., Medina, D., Naber, S. P., & Jerry, D. J. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64853-5 · Cited by 190
Activation of the JNK pathway is essential for transformation by the Met oncogene
Rodrigues, G. A. (1997) · The EMBO Journal · doi:10.1093/emboj/16.10.2634 · Cited by 187
Identification of a new JNK inhibitor targeting the JNK-JIP interaction site
Stebbins, J. L., De, S. K., Machleidt, T., Becattini, B., Vazquez, J., Kuntzen, C., Chen, L.-H., Cellitti, J. F., Riel-Mehan, M., Emdadi, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805677105 · Cited by 186
The role of JNK in the development of hepatocellular carcinoma
Das, M., Garlick, D. S., Greiner, D. L., & Davis, R. J. (2011) · Genes & Development · doi:10.1101/gad.1989311 · Cited by 186
Transformation suppressor activity of a Jun transcription factor lacking its activation domain
Lloyd, A., Yancheva, N., & Wasylyk, B. (1991) · Nature · doi:10.1038/352635a0 · Cited by 184
Su, G. H., Hilgers, W., Shekher, M. C., Tang, D. J., Yeo, C. J., Hruban, R. H., & Kern, S. E. (1998) · PubMed · Cited by 183
She, Q., Chen, N., Bode, A. M., Flavell, R. A., & Dong, Z. (2002) · PubMed · Cited by 173
The JIP family of MAPK scaffold proteins
Whitmarsh, A. J. (2006) · Biochemical Society Transactions · doi:10.1042/bst0340828 · Cited by 168
Context-specific inhibition of JNKs: overcoming the dilemma of protection and damage
WAETZIG, V, & HERDEGEN, T. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.07.006 · Cited by 166
Survival signaling mediated by c-Jun NH2-terminal kinase in transformed B lymphoblasts
Hess, P., Pihan, G., Sawyers, C. L., Flavell, R. A., & Davis, R. J. (2002) · Nature Genetics · doi:10.1038/ng946 · Cited by 165
JNK2 Is a Positive Regulator of the cJun Transcription Factor
Jaeschke, A., Karasarides, M., Ventura, J.-J., Ehrhardt, A., Zhang, C., Flavell, R. A., Shokat, K. M., & Davis, R. J. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.07.028 · Cited by 161
Wang, W., Shi, L., Xie, Y., Ma, C., Li, W., Su, X., Huang, S., Chen, R., Zhu, Z., Mao, Z., et al. (2004) · Neuroscience Research · doi:10.1016/j.neures.2003.10.012 · Cited by 160
Szczepankiewicz, B. G., Kosogof, C., Nelson, L. T. J., Liu, G., Liu, B., Zhao, H., Serby, M. D., Xin, Z., Liu, M., Gum, R. J., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060199b · Cited by 159
Mechanisms of liver disease: cross-talk between the NF-κB and JNK pathways
Papa, S., Bubici, C., Zazzeroni, F., & Franzoso, G. (2009) · bchm · doi:10.1515/bc.2009.111 · Cited by 156
Self-citationc-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells
Gururajan, M., Chui, R., Karuppannan, A. K., Ke, J., JENNINGS, C. D., & Bondada, S. (2005) · Blood · doi:10.1182/blood-2004-10-3819 · Cited by 156
Role of the JNK signal transduction pathway in inflammatory bowel disease
Roy, P. K., Rashid, F., Bragg, J. D., Ibdah, J. A., Hepatology, D. O. G. A., Columbia, Missouri, & States, U. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.200 · Cited by 150
Ferrandi, C., Ballerio, R., Gaillard, P., Giachetti, C., Carboni, S., Vitte, P., Gotteland, J., & Cirillo, R. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705873 · Cited by 148
Bost, F., McKay, R. A., Bost, M., Potapova, O., Dean, N. M., & Mercola, D. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.3.1938 · Cited by 146
Myeloid malignancies: mutations, models and management
Murati, A., Brecqueville, M., Devillier, R., Mozziconacci, M.-J., Gelsi-Boyer, V., & Birnbaum, D. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-304 · Cited by 139
Cooperation between JNK1 and JNK2 in activation of p53 apoptotic pathway
Oleinik, N. V., Krupenko, N. I., & Krupenko, S. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210526 · Cited by 135
c-Myc Augments Gamma Irradiation-Induced Apoptosis by Suppressing Bcl-X L
Maclean, K. H., Keller, U. B., Galindo, C. R., Nilsson, J. A., & Cleveland, J. L. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.20.7256-7270.2003 · Cited by 130
Gaillard, P., Jeanclaude-Etter, I., Ardissone, V., Arkinstall, S., Cambet, Y., Camps, M., Chabert, C., Church, D. J., Cirillo, R., Gretener, D., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0310986 · Cited by 129
Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer
Chang, Q., Zhang, Y., Beezhold, K., Bhatia, D., Zhao, H., Chen, J., Castranova, V., Shi, X., & Chen, F. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.07.037 · Cited by 127
Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor
Krenitsky, V. P., Nadolny, L., Delgado, M., Ayala, L., Clareen, S. S., Hilgraf, R., Albers, R., Hegde, S. G., D’Sidocky, N., Sapienza, J., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.12.027 · Cited by 121
C-Jun NH(2)-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma.
Yang, Y.-M., Bost, F., Charbono, W., Dean, N. S., McKay, R. A., Rhim, J. S., Depatie, C., & Mercola, D. (2003) · PubMed · Cited by 120
Barbarulo, A., Iansante, V., Chaidos, A., Naresh, K. N., Rahemtulla, A., Franzoso, G., Karadimitris, A., Haskard, D. O., Papa, S., & Bubici, C. (2012) · Oncogene · doi:10.1038/onc.2012.448 · Cited by 119
Self-citationGoenka, S., & Boothby, M. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506981103 · Cited by 115
Hagiwara, S., Kudo, M., Nagai, T., Inoue, T., Ueshima, K., Nishida, N., Watanabe, T., & Sakurai, T. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.145 · Cited by 115
Cho, S. H., Ahn, A., Bhargava, P., Lee, C., Eischen, C. M., McGuinness, O. P., & Boothby, M. R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017082108 · Cited by 113
Carboni, S., Hiver, A., Szyndralewiez, C., Gaillard, P., Gotteland, J., & Vitte, P. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.064246 · Cited by 110
Yoon, C., Kim, M.-J., Kim, R.-K., Lim, E.-J., Choi, K.-S., An, S., Hwang, S.-G., Kang, S.-G., Suh, Y., Park, M.-J., et al. (2012) · Oncogene · doi:10.1038/onc.2011.634 · Cited by 110
Ho, D. T., Bardwell, A. J., Abdollahi, M., & Bardwell, L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304229200 · Cited by 108
Elevated JNK activation contributes to the pathogenesis of human brain tumors
Antonyak, M. A., Kenyon, L. C., Godwin, A. K., James, D. C., Emlet, D. R., Okamoto, I., Tnani, M., Holgado-Madruga, M., Moscatello, D. K., & Wong, A. J. (2002) · Oncogene · doi:10.1038/sj.onc.1205593 · Cited by 106
PUMA–mediated apoptosis drives chemical hepatocarcinogenesis in mice
Qiu, W., Wang, X., Leibowitz, B. J., Yang, W., Zhang, L., & Yu, J. (2011) · Hepatology · doi:10.1002/hep.24516 · Cited by 102
The stress kinase MKK7 couples oncogenic stress to p53 stability and tumor suppression
Schramek, D., Kotsinas, A., Meixner, A., Wada, T., Elling, U., Pospisilik, J. A., Neely, G. G., Zwick, R. H., Sigl, V., Forni, G., et al. (2011) · Nature Genetics · doi:10.1038/ng.767 · Cited by 101
Targeting the JNK Signaling Pathway for Stroke and Parkinsons Diseases Therapy
Kuan, C.-Y., & Burke, R. E. (2005) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007053005145 · Cited by 99
Requirement of c-Jun NH 2 -Terminal Kinase for Ras-Initiated Tumor Formation
Cellurale, C., Sabio, G., Kennedy, N. J., Das, M., Barlow, M., Sandy, P., Jacks, T., & Davis, R. J. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01122-10 · Cited by 98
Constitutively active forms of c-Jun NH2-terminal kinase are expressed in primary glial tumors.
Tsuiki, H., Tnani, M., Okamoto, I., Kenyon, L. C., Emlet, D. R., Holgado-Madruga, M., Lanham, I. S., Joynes, C. J., Vo, K. T., & Wong, A. J. (2003) · PubMed · Cited by 98
Role of JNK in Mammary Gland Development and Breast Cancer
Cellurale, C., Girnius, N., Jiang, F., Cavanagh, J., Lu, S., Garlick, D. S., Mercurio, A. M., & Davis, R. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1628 · Cited by 97
c-Jun NH2-Terminal Kinase 1 Plays a Critical Role in Intestinal Homeostasis and Tumor Suppression
Tong, C., Yin, Z., Song, Z., Dockendorff, A., Huang, C., Mariadason, J. M., Flavell, R. A., Davis, R. J., Augenlicht, L. H., & Yang, W. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.061036 · Cited by 93
Nagata, H., Hatano, E., Tada, M., Murata, M., Kitamura, K., Asechi, H., Narita, M., Yanagida, A., Tamaki, N., Yagi, S., et al. (2009) · Hepatology · doi:10.1002/hep.22860 · Cited by 93
JNK1 activation predicts the prognostic outcome of the human hepatocellular carcinoma
Chang, Q., Chen, J., Beezhold, K., Castranova, V., Shi, X., & Chen, F. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-64 · Cited by 86
Biologic sequelae of IκB kinase (IKK) inhibition in multiple myeloma: therapeutic implications
Hideshima, T., Chauhan, D., Kiziltepe, T., Ikeda, H., Okawa, Y., Podar, K., Raje, N. S., Protopopov, A. I., Munshi, N. C., Richardson, P. G. G., et al. (2009) · Blood · doi:10.1182/blood-2008-06-161505 · Cited by 78
Small Molecule JNK (c-Jun N-Terminal Kinase) Inhibitors
Siddiqui, M. A., & Reddy, P. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm9003279 · Cited by 77
Multiple Myeloma: Lusting for NF-κB
Gilmore, T. D. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.07.010 · Cited by 77
Biologic sequelae of c-Jun NH2-terminal kinase (JNK) activation in multiple myeloma cell lines
Hideshima, T., Hayashi, T., Chauhan, D., Akiyama, M., Richardson, P. G. G., & Anderson, K. C. (2003) · Oncogene · doi:10.1038/sj.onc.1206919 · Cited by 76
c-Jun NH2-Terminal Kinase 2α2 Promotes the Tumorigenicity of Human Glioblastoma Cells
Cui, J., Han, S., Wang, C., Su, W., Harshyne, L. A., Holgado-Madruga, M., & Wong, A. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0136 · Cited by 75
Gao, Y., Cheng, J. K., Zeng, Q., Xu, Z., Décosterd, I., Xu, X., & Ji, R. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.05.006 · Cited by 70
Kamenecka, T., Jiang, R., Song, X., Duckett, D. R., Chen, W., Ling, Y. Y., Habel, J. E., Laughlin, J. D., Chambers, J. W., Figuera-Losada, M., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901351f · Cited by 69
Ronaldson, P. T., Ashraf, T., & Bendayan, R. (2010) · Molecular Pharmacology · doi:10.1124/mol.109.059410 · Cited by 69
Wang, Q., Salman, H., Danilenko, M., & Studzinski, G. P. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20355 · Cited by 68
Mutation rate of MAP2K4/MKK4 in breast carcinoma
Su, G. H., Song, J. J., Repasky, E. A., Schutte, M. E. M., & Kern, S. E. (2001) · Human Mutation · doi:10.1002/humu.9002 · Cited by 64
Cripe, L. D., Gelfanov, V. M., Smith, E., Spigel, D., Phillips, C., Gabig, T. G., Jung, S.-H., Daggy, J., Hartman, A. D., Kneebone, P. H., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402457 · Cited by 63
Yoshida, S., Fukino, K., Harada, H., et al. (2001) · Journal of Human Genetics · doi:10.1007/s100380170086 · Cited by 60
Mucha, S. R., Rizzani, A., Gerbes, A. L., Čamaj, P., Thasler, W. E., Bruns, C. J., Eichhorst, S. T., Gallmeier, E., Kolligs, F. T., Göke, B., et al. (2008) · Gut · doi:10.1136/gut.2008.154625 · Cited by 58
Identification of small-molecule inhibitors of the JIP–JNK interaction
Chen, T. X., Kablaoui, N. M., Little, J., Timofeevski, S. L., Tschantz, W. R., Chen, P., Feng, J., Charlton, M. E., Stanton, R. V., & Bauer, P. H. (2009) · Biochemical Journal · doi:10.1042/bj20081899 · Cited by 57
Cui, J., Wang, Q., Wang, J., Lv, M., Zhu, N., Li, Y., Feng, J., Shen, B., & Zhang, J. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0408 · Cited by 55
The c-Jun NH2-Terminal Kinase 2 Plays a Dominant Role in Human Epidermal Neoplasia
Ke, H., Harris, R., Coloff, J. L., Jin, J. Y., Leshin, B., de Marval, P. L. M., Tao, S., Rathmell, J. C., Hall, R. P., & Zhang, J. Y. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2923 · Cited by 55
Development of JNK2-Selective Peptide Inhibitors That Inhibit Breast Cancer Cell Migration
Kaoud, T. S., Mitra, S., Lee, S., Taliaferro, J. M., Cantrell, M. A., Linse, K. D., Berg, C. L. V. D., & Dalby, K. N. (2011) · ACS Chemical Biology · doi:10.1021/cb200017n · Cited by 50
The JNK Inhibitor XG-102 Protects against TNBS-Induced Colitis
Reinecke, K., Eminel, S., Dierck, F., Roessner, W., Kersting, S., Chromik, A. M., Gavrilova, O., Laukevicience, A., Leuschner, I., Waetzig, V., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030985 · Cited by 49
The role of the c-Jun N-terminal Kinase signaling pathway in skin cancer.
Zhang, J. Y., & Selim, M. A. (2012) · PubMed · Cited by 48
Li, J. Y., Wang, H., May, S., Song, X., Fueyo, J., Fuller, G. N., & Wang, H. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9529-1 · Cited by 48
Chen, P., O’Neal, J. F., Ebelt, N. D., Cantrell, M. A., Mitra, S., Nasrazadani, A., Vandenbroek, T. L., Heasley, L. E., & Berg, C. L. V. D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010443 · Cited by 47
Tumor Necrosis Factor Receptor 1/c-Jun-NH2-Kinase Signaling Promotes Human Neoplasia
Zhang, J. Y., Adams, A. E., Ridky, T. W., Tao, S., & Khavari, P. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4017 · Cited by 47
An inhibitory function for JNK in the regulation of IGF-I signaling in breast cancer
Mamay, C. L., Mingo-Sion, A. M., Wolf, D., Molina, M. D. C., & Berg, C. L. V. D. (2003) · Oncogene · doi:10.1038/sj.onc.1206186 · Cited by 44
Role of JNK in a Trp53-Dependent Mouse Model of Breast Cancer
Cellurale, C., Weston, C. R., Reilly, J., Garlick, D. S., Jerry, D. J., Sluss, H. K., & Davis, R. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012469 · Cited by 43
The Mitogen-Activated Protein Kinase Kinase 4 Has a Pro-Oncogenic Role in Skin Cancer
Finegan, K. G., & Tournier, C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3669 · Cited by 41
JNK1 Is Essential for CD8+ T Cell-Mediated Tumor Immune Surveillance
Gao, Y., Tao, J., Li, M. O., Zhang, D., Chi, H., Henegariu, O., Kaech, S. M., Davis, R. J., Flavell, R. A., & Yin, Z. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.5783 · Cited by 40
Inhibitors of c-jun-N-Terminal Kinase (JNK)
LoGrasso, P. V., & Kamenecka, T. M. (2008) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955708784912120 · Cited by 40
Genetic Deletion of JNK1 and JNK2 Aggravates the DSS-Induced Colitis in Mice
Chromik, A. M., Müller, A. M., Körner, J., Belyaev, O., Holland‐Letz, T., Schmitz, F., Herdegen, T., Uhl, W. H., & Mittelkötter, U. (2007) · Journal of Investigative Surgery · doi:10.1080/08941930601126140 · Cited by 35
Basal Cancer Cell Survival Involves JNK2 Suppression of a Novel JNK1/c-Jun/Bcl-3 Apoptotic Network
Ahmed, S. U., & Milner, J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007305 · Cited by 35
The role of the c-Jun N-terminal kinase 2-α-isoform in non-small cell lung carcinoma tumorigenesis
Nitta, R. T., Fitz, C. D. V., Chu, A., Mitra, S. S., Godwin, A. K., & Wong, A. J. (2010) · Oncogene · doi:10.1038/onc.2010.414 · Cited by 33
c-Jun N-Terminal Kinase 1 Phosphorylates Myt1 To Prevent UVA-Induced Skin Cancer
Choi, H. S., Bode, A. M., Shim, J., Lee, S., & Dong, Z. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01508-08 · Cited by 31
Characterization of a novel JNK (c-Jun N-terminal kinase) inhibitory peptide
Ngoei, K. R. W., Catimel, B., Church, N., Lio, D. S., Dogovski, C., Perugini, M. A., Watt, P. M., Cheng, H.-C., Ng, D. C. H., & Bogoyevitch, M. A. (2011) · Biochemical Journal · doi:10.1042/bj20101244 · Cited by 31
Yan, F., Wang, X., Liu, Z.-C., Pan, C., Yuan, S.-B., & Ma, Q.-M. (2010) · PubMed · Cited by 30
Kersting, S., Behrendt, Kersting, Reinecke, Hilgert, Stricker, Herdegen, Janot-Matuschek, M. S., Uhl, & Chromik (2013) · Journal of Inflammation Research · doi:10.2147/jir.s40092 · Cited by 28
A selective small‐molecule inhibitor of c‐Jun N‐terminal kinase 1
Yao, K., Cho, Y., Bode, A. M., Vummenthala, A., Park, J. G., Liu, K., Pang, Y., & Dong, Z. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.06.017 · Cited by 15
Identification and characterization of bi-thiazole-2,2′-diamines as kinase inhibitory scaffolds
Ngoei, K. R. W., Ng, D. C. H., Gooley, P. R., Fairlie, D. P., Stoermer, M. J., & Bogoyevitch, M. A. (2013) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2013.02.001 · Cited by 10
Cited by
Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity
Lee, S., Rauch, J., & Kolch, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031102 · Cited by 799
Extracellular ATP and P2 purinergic signalling in the tumour microenvironment
Di Virgilio, F., Sarti, A. C., Falzoni, S., De Marchi, E., & Adinolfi, E. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0037-0 · Cited by 723
The ERK and JNK pathways in the regulation of metabolic reprogramming
Papa, S., Choy, P. M., & Bubici, C. (2019) · Oncogene · doi:10.1038/s41388-018-0582-8 · Cited by 381
Self-citationThorsell, A.-G., Ekblad, T., Karlberg, T., Löw, M., Pinto, A. F., Trésaugues, L., Moche, M., Cohen, M. S., & Schüler, H. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00990 · Cited by 358
JNK signaling in cancer cell survival
Wu, Q., Wu, W., Fu, B., Shi, L., Wang, X., & Kuca, K. (2019) · Medicinal Research Reviews · doi:10.1002/med.21574 · Cited by 322
Metadata
- Authors
- Bubici, C., & Papa, S.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2013-12-10
- Volume
- 171
- Issue
- 1
- Pages
- 24-37
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1598771153
- Cited by
- 346
- References
- 135
- FWCI
- 8.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.